勃起功能障碍治疗与心肌梗死后死亡或心血管结局的关联
与未接受ED治疗者相比,接受ED治疗者死亡风险降低33%(校正HR 0.67,95%CI 0.55-0.81),心衰住院风险降低40%(HR 0.60,95%CI 0.44-0.82)。仅磷酸二酯酶-5抑制剂治疗者风险降低,且呈剂量依赖性。
要点
- 首次心梗后接受ED治疗与全因死亡风险降低33%相关(校正HR 0.67)。
- ED治疗与心衰住院风险降低40%相关(HR 0.60)。
- 仅磷酸二酯酶-5抑制剂治疗者风险降低,且随处方数增加呈剂量依赖性。
核心结论
- 首次心梗后接受ED治疗与死亡和心衰住院风险降低相关。
- 仅磷酸二酯酶-5抑制剂治疗者风险降低,且呈剂量依赖性。
研究设计与样本
- 瑞典全国队列研究,纳入2007-2013年因心梗住院的<80岁、无既往心梗或血运重建史的男性。
- ED治疗定义为配发磷酸二酯酶-5抑制剂或前列地尔。
主要发现
- 7.1%的男性在随访期间配发了ED药物。
- 与未接受ED治疗者相比,接受ED治疗者全因死亡风险降低33%(校正HR 0.67,95%CI 0.55-0.81)。
- 与未接受ED治疗者相比,接受ED治疗者心衰住院风险降低40%(HR 0.60,95%CI 0.44-0.82)。
- 与前列地尔治疗相比,配发1次、2-5次和>5次磷酸二酯酶-5抑制剂处方者的死亡风险分别降低34%(HR 0.66,95%CI 0.38-1.15)、53%(HR 0.47,95%CI 0.26-0.87)和81%(HR 0.19,95%CI 0.08-0.45)。
- 前列地尔治疗与死亡率无关联。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Erectile dysfunction (ED) is associated with an increased risk of cardiovascular disease in healthy men. However, the association between treatment for ED and death or cardiovascular outcomes after a first myocardial infarction (MI) is unknown. METHODS: In a Swedish nationwide cohort study all men <80 years of age without prior MI, or cardiac revascularisation, hospitalised for MI during 2007-2013 were included. Treatment for ED, defined as dispensed phosphodiesterase-5 inhibitors or alprostadil, was related to risk of death, MI, cardiac revascularisation or heart failure. RESULTS: Forty-three thousand one hundred and forty-five men with mean age 64 (±10) years were included, of whom 7.1% had ED medication dispensed during a mean 3.3 years (141 739 person-years) of follow--up. Men with, compared with those without treatment for ED, had a 33% lower mortality (adjusted HR 0.67 (95%CI 0.55 to -0.81)), and 40% lower risk of hospitalisation for heart failure (HR 0.60 (95% CI 0.44 to 0.82)). There was no association between treatment with alprostadil and mortality. The adjusted risk of death in men with 1, 2-5 and >5 dispensed prescriptions of phosphodiesterase-5 inhibitors was reduced by 34% (HR 0.66 (95% CI 0.38 to 1.15), 53% (HR 0.47 (95% CI 0.26 to 0.87) and 81% (HR 0.19 (95% CI 0.08 to 0.45), respectively, when compared with alprostadil treatment. CONCLUSIONS: Treatment for ED after a first MI was associated with a reduced mortality and heart failure hospitalisation. Only men treated with phosphodiesterase-5 inhibitors had a reduced risk, which appeared to be dose-dependent.
引用
- Andersson DP, Trolle Lagerros Y, Grotta A, et al. Association between treatment for erectile dysfunction and death or cardiovascular outcomes after myocardial infarction. Heart. 2017. PMID: 28280146. doi:10.1136/heartjnl-2016-310746
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。